1. Home
  2. HTCO vs SKYE Comparison

HTCO vs SKYE Comparison

Compare HTCO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTCO
  • SKYE
  • Stock Information
  • Founded
  • HTCO N/A
  • SKYE 2012
  • Country
  • HTCO Singapore
  • SKYE United States
  • Employees
  • HTCO N/A
  • SKYE N/A
  • Industry
  • HTCO
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTCO
  • SKYE Health Care
  • Exchange
  • HTCO NYSE
  • SKYE Nasdaq
  • Market Cap
  • HTCO 92.5M
  • SKYE 108.3M
  • IPO Year
  • HTCO N/A
  • SKYE N/A
  • Fundamental
  • Price
  • HTCO $1.17
  • SKYE $4.94
  • Analyst Decision
  • HTCO
  • SKYE Buy
  • Analyst Count
  • HTCO 0
  • SKYE 6
  • Target Price
  • HTCO N/A
  • SKYE $18.67
  • AVG Volume (30 Days)
  • HTCO 159.1K
  • SKYE 308.0K
  • Earning Date
  • HTCO 11-01-2024
  • SKYE 11-09-2024
  • Dividend Yield
  • HTCO N/A
  • SKYE N/A
  • EPS Growth
  • HTCO N/A
  • SKYE N/A
  • EPS
  • HTCO N/A
  • SKYE N/A
  • Revenue
  • HTCO $95,257,538.00
  • SKYE N/A
  • Revenue This Year
  • HTCO N/A
  • SKYE N/A
  • Revenue Next Year
  • HTCO N/A
  • SKYE N/A
  • P/E Ratio
  • HTCO N/A
  • SKYE N/A
  • Revenue Growth
  • HTCO N/A
  • SKYE N/A
  • 52 Week Low
  • HTCO $0.21
  • SKYE $1.44
  • 52 Week High
  • HTCO $1.63
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • HTCO N/A
  • SKYE 58.26
  • Support Level
  • HTCO N/A
  • SKYE $4.01
  • Resistance Level
  • HTCO N/A
  • SKYE $5.48
  • Average True Range (ATR)
  • HTCO 0.00
  • SKYE 0.46
  • MACD
  • HTCO 0.00
  • SKYE 0.19
  • Stochastic Oscillator
  • HTCO 0.00
  • SKYE 73.79

About HTCO CARAVELLE INTERNATIONAL GROUP

Caravelle International Group is an international operator of ocean transportation services. It is engaged in the seaborne transportation service under voyage contracts as well as vessel service for and on behalf of ship owners. The company has two operating segments namely, ocean transport and Heating business. The company derives the majority of its revenue from the Ocean transportation business. The company derives freight revenue from voyage contracts and provides vessel service.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: